Quidel Corp. (NSDQ:QDEL) landed a nod from the Food & Drug Administration for its new pregnancy test platform.
The RapidVue dipstick-format pregnancy immunoassay will be the San Diego-based diagnostics company’s fourth product launched this year, according to a press release.
Quidel designed the human chorionic gonadotropin-based test to be used with urine samples. The company said test results are available three minutes after use.
In February, Quidel completed a $130 million cash acquisition of Athens, Ohio-based cellular and molecular diagnostic kit developer Diagnostic Hybrids Inc.